| Warner Chilcott Public Limited Company - SWOT | | | | Europe. WC acquired the global branded |
| Analysis company profile is the essential source for | | | | pharmaceuticals business of P&G on October 30, |
| top-level company data and information. Warner | | | | 2009. The company is headquartered Ardee, Ireland, |
| Chilcott Public Limited Company - SWOT Analysis | | | | and employed 2,700 people as of December 31, |
| examines the company's key business structure and | | | | 2009. The company recorded revenues of $1,435.8 |
| operations, history and products, and provides | | | | million during the financial year (FY) ended December |
| summary analysis of its key revenue lines and | | | | 2009, an increase of 53.1% over FY2008. The |
| strategy. | | | | operating profit of the company was $600.4 million |
| Warner Chilcott PLC (WC), formerly Warner Chilcott | | | | during FY2009, an increase of 20.9% over FY2008. |
| Limited, is a specialty pharmaceutical company. WC is | | | | The net profit was $514.1 million in FY2009, as |
| engaged in the development, manufacture and | | | | compared to a net loss of $8.4 million in FY2008. The |
| marketing of branded prescription pharmaceutical | | | | significant increase in revenues and profits in FY2009 |
| products in gastroenterology, women's healthcare, | | | | was primarily due to the acquisition of P&G's |
| dermatology and urology segments. The company | | | | global prescription pharmaceutical business. |
| primarily operates in North America and Western | | | | |